Albion Financial Group’s West Pharmaceutical WST Stock Holding History

Albion Financial Group’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9	Closed	-$4K	–	635
2022 Q1	$4K	Buy	+9	New	+$3.52K	﹤0.01%	434

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Albion Financial Group's WST Position: Q2 2022 in Review

Albion Financial Group sold out of West Pharmaceutical (WST) in Q2 2022, closing a stake of 9 shares — an estimated $4K sold.

Albion Financial Group first reported a position in WST in Q1 2022 and held it in 1 quarter. The position peaked at $4K in Q1 2022. 655 funds tracked by Wall St. Rank hold WST as of Q2 2022.

Albion Financial Group reported no remaining West Pharmaceutical position as of Q2 2022 after selling out during the quarter.
Albion Financial Group sold 9 West Pharmaceutical shares in Q2 2022, an estimated $4K.
Albion Financial Group first reported a position in West Pharmaceutical in Q1 2022 and held it in 1 quarter.
Albion Financial Group's West Pharmaceutical position peaked at $4K in Q1 2022.
655 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2022.

Based on Albion Financial Group's 13F filing for Q2 2022, filed 29 Jul 2022.